TESARO, Inc. (NASDAQ:TSRO)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report released on Monday. They currently have a $160.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price target would suggest a potential upside of 34.82% from the company’s current price.

Several other brokerages have also weighed in on TSRO. Cann reissued a “buy” rating and set a $199.00 target price on shares of TESARO in a research report on Monday, June 5th. Citigroup Inc. reissued a “buy” rating and set a $216.00 target price on shares of TESARO in a research report on Monday. Robert W. Baird reissued a “neutral” rating and set a $140.00 target price (down previously from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Cowen and Company cut their target price on TESARO from $145.00 to $124.00 and set a “market perform” rating on the stock in a research report on Monday, June 19th. Finally, Credit Suisse Group set a $190.00 target price on TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $175.15.

Shares of TESARO (TSRO) traded down 1.36% during midday trading on Monday, hitting $118.68. The stock had a trading volume of 791,530 shares. TESARO has a one year low of $90.56 and a one year high of $192.94. The firm has a 50 day moving average price of $123.28 and a 200 day moving average price of $142.28. The stock’s market cap is $6.43 billion.

TESARO (NASDAQ:TSRO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by $0.30. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. During the same period last year, the business posted ($1.28) EPS. TESARO’s revenue was down 17.6% on a year-over-year basis. On average, equities analysts forecast that TESARO will post ($8.67) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/11/tesaro-inc-tsro-stock-rating-reaffirmed-by-wedbush.html.

In related news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total value of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at $844,329.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,100 shares of company stock worth $3,387,465. Company insiders own 34.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. FMR LLC raised its holdings in TESARO by 0.4% during the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock worth $1,237,718,000 after purchasing an additional 32,918 shares during the last quarter. BlackRock Inc. raised its holdings in shares of TESARO by 5.7% in the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after acquiring an additional 195,590 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of TESARO by 2.1% in the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after acquiring an additional 62,104 shares during the last quarter. State Street Corp raised its holdings in shares of TESARO by 17.9% in the second quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after acquiring an additional 177,057 shares during the last quarter. Finally, BB Biotech AG raised its holdings in shares of TESARO by 6.5% in the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after acquiring an additional 53,408 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.